Teva’s AJOVY Receives FDA Approval for the Treatment of Migraine in Adults with Monthly and Quarterly Dosing

 Teva’s AJOVY Receives FDA Approval for the Treatment of Migraine in Adults with Monthly and Quarterly Dosing

Teva’s AJOVY Receives FDA Approval for the Treatment of Migraine in Adults with Monthly and Quarterly Dosing

Shots:

  • AJOVY (remanezumab-vfrm) is evaluated in two P-III trial enrolling patients with disabling migraine, administering AJOVY alone and in combination with oral preventive treatments, showing reduction in monthly migraine days in 12 wks. duration having injection site reactions as adverse effects
  • The US Wholesale Acquisition Cost (WAC) of AJOVY for monthly and the quarterly dose is $575 & $1,725 respectively, will be available within two weeks
  • AJOVY SC injection will be marketed as 225 mg/1.5mL single dose in a prefilled syringe having two dosage options 225 mg/monthly as one SC IV, or 675 mg q3months as three SC IV

Click here to read full press release/ article | Ref: Teva | Image:  Irish Times

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post